Corporate Profile  

Target Market 
 

Business Strategy
Our Story

Chairman's Message

Co-Founder's Message

Mission Statement

Officers & Key Personnel

Scientific Advisory Board

   
Mission Statement  
 

See The President's Message on 2005 & 2006

 

Vision: The purpose and development of CardioVascular BioTherapeutics, Inc. is to assist in extending life through the use of FGF-1141, our drug candidate that addresses cardiovascular disease by increasing the blood supply to ischemic areas, organs and tissues of the body. Once blood perfusion is established through the growth of new blood vessels in areas affected, patients with cardiovascular disease can experience an increase in life expectancy and quality of life.

Mission: Our mission at CardioVascular BioTherapeutics, Inc. is to provide treatment for different types of cardiovascular disease.  CVBT is determined to achieve this primary goal and accomplish this humanitarian objective, which could potentially help millions of people who suffer from such diseases.

Our Goals: CVBT must accomplish three key goals in order to succeed in its mission:

  1. Become a commercially viable business.
  2. Conduct our actions in a manner that allows everyone to trust in our integrity to do the right thing.
  3. Continue to identify and develop revolutionary new medical treatments for the number one cause of death in the developed world.

 

 

 

 

 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.

 

7/1/2008
Dutton Associates Announces Investment Opinion: CardioVascular BioTherapeutics Maintained At Neutral Rating By Dutton Associates


6/10/2008
CVBT Inks Third Clinical Development Agreement


5/22/2008
Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial


4/24/2008
CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership